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Anticancer activity of tetracationic arene ruthenium metalla-cycles
Nicolas P. E. Barry,a Fabio Edafeb and Bruno Therrien*a
A series of cationic metalla-cycles of the general formulae [(h6-p-cym)4Ru4(OO«OO)2(N«N)2]4+ and
[(h6-p-cym)4Ru4(NO«NO)2(N«N)2]4+ has been prepared from the dinuclear arene ruthenium precursors
[(h6-p-cym)2Ru2(OO«OO)2Cl2] (OO«OO = oxalato, 1,4-benzoquinonato-2,5-diolato, 1,4-naphtoquinonato-5,8-diolato,
9,10-anthraquinonato-1,4-diolato, 5,12-tetraquinonato-6,11-diolato) and [(h6-p-cym)2Ru2(NO«NO)2Cl2]
(NO«NO = oxamido, oxonico) by reaction with two different bidentate linkers
(N«N = 1,2-bis(4-pyridyl)ethylene, 1,2-bis(4-pyridyl)ethane) in the presence of silver triﬂate. All complexes were isolated as triﬂate
salts and characterised by NMR, infrared, UV-visible, mass spectrometry and by elemental analysis. The cytotoxicities of the
tetranuclear ruthenium complexes have been established using ovarian A2780 and A2780cisR cancer cell lines. All complexes exhibit
moderate to excellent activity on both the cisplatin resistant and cisplatin sensitive cells, thus suggesting a mode of action different
from cisplatin.
Introduction
The design of molecular hosts to encapsulate guest molecules
in a conﬁned environment is receiving considerable attention
due to the analogy of these systems with the mode of action
of enzymes. Pioneered by Cram, Lehn and Pedersen,1 winners
of the Nobel Prize in chemistry in 1987 for their contributions
to the development and use of molecules with structure-speciﬁc
interactions of high selectivity, synthetic molecular hosts were
initially dominated by purely organic molecules: cyclodextrins,
carcerands, cryptands, cucurbiturils, cavitands.2 However, the last
twenty years have seen the emergence of discrete inorganic and
organometallic metalla-hosts able to encapsulate temporary or
permanently various guest molecules in their cavity, thus opening
new perspectives in coordination chemistry.3 In analogy to crown-
ethers, 15 years ago, Fish and his co-workers have prepared
a series of trinuclear metalla-cycles composed of half-sandwich
complexes and adenine-derivative ligands.4 Molecular modelling
suggested classical p–p interactions between the aromatic groups
of various substituted aromatic carboxylic acids and the cavity
of the trinuclear hosts. Using a similar strategy, other trinuclear
metalla-cycles have been isolated,5 and nowadays, tetranuclear6
as well as hexanuclear metalla-cycles7 composed of half-sandwich
complexes can be found in the literature. For example, trinuclear
metalla-cycles derived from half-sandwich complexes and 2,3-
dihydroxypyridine ligands have been found to possess high afﬁnity
for lithium and sodium salts, thus giving rise to potential sensors.8
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Moreover, it was found that tetranuclear arene rutheniummetalla-
cycles interact strongly with DNA9 and are cytotoxic on various
cancer cell lines.10 Similarly, cationic tetranuclear arene osmium
metalla-cycles have shown cytotoxicity on human ovarian cancer
cells.11 These examples conﬁrm the potential of using metalla-
cycles composed of half-sandwich complexes to prepare biological
agents. Among these half-sandwich complexes for biological ap-
plications, arene ruthenium complexes are probably the derivatives
receiving the greatest attention.12
Since 2008, we are exploiting the combination of supramolec-
ular chemistry of half-sandwich building blocks with the
antitumoral and antimetastatic activity of arene ruthenium
complexes.13 It has been demonstrated that water-soluble
arene ruthenium metalla-assemblies are stable in biological
medium, exhibit antiproliferative activity, and they can act
as drug carriers. This approach has led to the synthesis
of tetranuclear metalla-cycles,14 hexanuclear metalla-prisms,15
as well as octanuclear metalla-boxes.16 In particular, tetranu-
clear arene ruthenium metalla-cycles of the general formula
[(h6-arene)4Ru4(OO«OO)2(N«N)2]4+ (arene = para-cymene (p-
cym), hexamethylbenzene (hmb);OO«OO= 1,4-benzoquinonato-
2,5-diolato (dobq), 3,6-dichlorido-1,4-benzoquinonato (dcbq);
N«N = pyrazine (pyr), 4,4¢-bipyridine (bpy), 1,2-bis(4-
pyridyl)ethylene (bpe)) have been tested against cancer cells. The
activity of these metalla-cycles against human ovarian cancer
cell lines (A2780 and A2780cisR) was found to be moderate to
excellent, depending on the size of the linker used as well as the
nature of the arene ligand (p-cym, hmb), with IC50 values as low
as 4 mM.17
To further study the antiproliferative activity of arene
ruthenium metalla-cycles, we propose to investigate the role
played by the linkers as well as the role played by the
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length and nature of the metalla-clips in the cytotoxicity of
tetranuclear metalla-cycles. Herein, we describe the synthe-
sis and the characterisation of 14 metalla-cycles of the gen-
eral formulae [(h6-p-cym)4Ru4(OO«OO)2(N«N)2]4+ and [(h6-p-
cym)4Ru4(NO«NO)2(N«N)2]4+ (OO«OO = oxalato (ox), dobq,
1,4-naphtoquinonato-5,8-diolato (donq), 9,10-anthraquinonato-
1,4-diolato (doaq), 5,12-tetraquinonato-6,11-diolato (dotq);
NO«NO = oxamido (oxa), oxonico (oxo); N«N = bpe, 1,2-bis(4-
pyridyl)ethane (bpa)), prepared from the dinuclear complexes
CL1Cl2–CL7Cl2 (see Chart 1). In addition, the in vitro anticancer
activity of these arene ruthenium metalla-cycles against human
ovarian cancer cell lines (A2780 and A2780cisR) is reported and
compared to cisplatin.
Results and discussion
Synthesis and characterisation
The synthesis of the arene rutheniummetalla-cycles incorporating
1,2-bis(4-pyridyl)ethylene (bpe) linkers, 2a,14b 4a,17 5a,15b 6a,14a and
7a,14a is straightforward, as previously described in the literature.
Accordingly, the preparation of the 1,2-bis(4-pyridyl)ethane (bpa)
derivatives involves the addition of four equivalents of silver
triﬂate to two equivalents of the dinuclear metalla-clips [(h6-p-
cym)2Ru2(OO«OO)2Cl2] (OO«OO = ox, dobq, donq, doaq, dotq)
(CL2Cl2 and CL4Cl2–CL7Cl2) in the presence of two equivalents
of bpa. These tetracationic metalla-cycles (2b, 4b, 5b, 6b, and 7b)
are isolated in good yield as triﬂate salts. All arene ruthenium
metalla-cycles used in this study are presented in Fig. 1.
Following the same strategy in which the new dinuclear com-
plex [(h6-p-cym)2Ru2(oxa)2Cl2] (CL1Cl2) and the already known
dinuclear complex [(h6-p-cym)2Ru2(oxo)2Cl2]9 (CL3Cl2) are used
as metalla-clips with bpe and bpa as N«N linkers, the salts
[1a:1b][CF3SO3]4 and [3a:3b][CF3SO3]4 have been prepared. These
new metalla-cycles were isolated as triﬂate salts and fully charac-
terised.
The solubility of all metalla-cycles is quite high in
dichloromethane, acetonitrile, acetone and dimethyl sulfoxide but
low in methanol and water. However, in the case of the bpa
derivatives (1b–7b) a higher water-solubility is observed. The
stability of all metalla-cycles is excellent in a mixture of D2O and
DMSO-d6 (50 : 50; v : v) as monitored by 1H NMR in which after
12 h of heating at 37 ◦C, no degradation was observed. Salts
[1a–7a][CF3SO3]4 and [1b–7b][CF3SO3]4 have been characterised
by IR, UV-visible, NMR spectroscopy, mass spectrometry and by
elemental analysis.
Fig. 1 Metalla-cycles 1a–7a and 1b–7b.
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The infrared spectra of all the metalla-cycles are dominated
by absorptions of the coordinated N«N, OO«OO and NO«NO
ligands, which are only slightly shifted as compared to the infrared
absorptions of the free ligands. In all metalla-clips as well as
in all metalla-cycles, a signiﬁcant redshift of about 20 cm-1 is
observed for the C O vibration frequencies as compared to
the frequencies of non-coordinated bridging ligands. This can be
attributed to a decrease in the CO bond order upon coordination
with ruthenium atoms.18 This decrease of the CO bond order
leading to a redshift of the CO absorption is consistent with the
X-ray data of the dinuclear complex [CL5(OH2)2]2+,19 for which
the lengths of the CO bonds are comprised between 1.27(1) A˚ and
1.32(2) A˚, suggesting an intermediate bond order between single
(~1.40 A˚) and double (~1.20 A˚).20 Furthermore, in metalla-cycles
3a and 3b strong absorptions due to the stretching vibrations of
C N oxonico bridging ligands are observed at around 1710 cm-1
alongside the absorptions of the stretching vibrations of the C O
bridging ligands at around 1600 cm-1. In addition to these CN and
CO signals, strong absorptions due to the stretching vibrations of
the triﬂate anions (1260(s), 1030(s), 638(m) cm-1) are observed
in the infrared spectra of all the salts [1a–7a][CF3SO3]4 and [1b–
7b][CF3SO3]4.
The electronic absorption spectra of all metalla-cycles are
characterised by an intense high-energy band centred at 270 nm,
which is attributed to ligand p → p* transitions.21 A broad,
moderately intense absorption band in the visible region (see
inset in Fig. 2) is tentatively assigned to mixed metal-to-ligand
charge transfer (MLCT), intra-ligand charge transfer (ILCT) and
ligand p → p* transitions, where ILCT refers to intra-ligand
charge transfer from the bpe or bpa N«N linkers to the OO«OO
or NO«NO bridging ligands.22 Moreover, in the metalla-cycles
incorporatingquinonederivatives (4a–7a and 4b–7b) several bands
attributed to ILCT are observed in the visible region between 500
and 800 nm. The UV-visible spectra in dichloromethane (10-5 M)
of metalla-cycles 1b–7b are presented in Fig. 2.
Moreover, bathochromic shifts are observed between the
arene ruthenium metalla-cycles incorporating the 1,2-bis(4-
pyridyl)ethylene linkers (5a–7a) and the metalla-cycles incorpo-
rating the 1,2-bis(4-pyridyl)ethane linkers (5b–7b). This signiﬁcant
bathochromic shift of up to 13 nm of lmax in the case of 7a:7b is
presumably due to a lower contribution to intra-ligand charge
transfer transitions (ILCT) from the bpa linkers to the OO«OO
bridging ligands as compared to the same ILCT frombpe linkers to
the corresponding quinone bridging ligands.23 The bathochromic
shifts of absorption bands of metalla-cycles 5a:5b, 6a:6b and 7a:7b
between 550 and 800 nm are depicted in Fig. 3.
Fig. 3 Bathochromic effect observed in the UV-visible spectra of 5a:5b
(---), 6a:6b ( ◊ ◊ ◊ ) and 7a:7b ( ) (CH2Cl2, 10-5 M).
The 1H NMR spectra of 2b and 4b–7b display two doublets
between 7.0 and 9.0 ppm due to the pyridyl protons of the bpa
ligands. Unlike free bpa, where the signals of the pyridyl protons
are found at d = 8.54 (Ha) and 7.21 ppm (Hb) respectively (CD3CN,
21 ◦C), the signal of Ha in 2b and 4b–7b appears slightly to
strongly upﬁeld shifted (up to 0.80 ppm in the case of 2b), while
the signal of Hb is either shifted upﬁeld (2b, 4b, 5b) or downﬁeld
(6b and 7b). The same behaviour is observed for the metalla-
cycles incorporating the bpe linkers, where a signiﬁcant upﬁeld
shift of the Ha signal (up to 0.75 ppm) and either an upﬁeld or
downﬁeld shift of the Hb signal are observed. Singlet associated
Fig. 2 UV-visible spectra of [1b–7b][CF3SO3]4 in CH2Cl2 (10-5 M).
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of the ethane protons in compounds 1b–7b (broad in the case of
3b) is observed at around 3.30 ppm. This important upﬁeld shift
of about 0.40 ppm for this signal as compared to the chemical
shift of the ethane signals in free bpa (2.92 ppm in CD3CN, 21 ◦C)
is characteristic of the formation of metalla-cycles.24 Indeed, this
observation is in accordance with the chemical displacement of
the ethylene protons observed in complexes 1a–7a where such an
upﬁeld shift (~0.30 ppm) is observed for the HC C signals. Finally,
the arene protons and the protons of the OO«OO and NO«NO
bridging ligands are not strongly inﬂuenced by the cyclisation and
show almost the same chemical shifts in both the metalla-cycles
and the dinuclear metalla-clips (CL1Cl2–CL7Cl2).14
It is noteworthy that among the sevendinuclear arene ruthenium
precursors, three are potentially chiral, CL1Cl2, CL3Cl2 and
CL6Cl2 respectively. These dinuclear complexes possess the ability
to form racemic and meso stereoisomers (Fig. 4), if the chlorido
ligands are not sterically restricted to coordinate at particular
positions. In addition, the two diastereoisomers can be observed
by NMR spectroscopy only if the metal centres are conﬁgura-
tionally stable in solution.25 Nevertheless, upon formation of the
corresponding tetranuclear metalla-cycles 1, 3 and 6, and despite
the presence of four stereogenic ruthenium centres, only two
diastereoisomers are observed. The two isomers observed in 1
are presented in Fig. 5.
Fig. 4 Racemic and meso stereoisomers of metalla-clip CL1Cl2.
Indeed, in the 1H NMR spectra of metalla-cycles 1a:1b and
3a:3b (see Fig. 6) the presence of these two isomers leads to
two distinct sets of signals for the pyridyl protons Ha and Hb
(CD3CN, 21 ◦C). Furthermore in metalla-cycles 1a and 3a the
two sets of signals are relatively broad and present almost similar
chemical shifts, while in 1b and 3b the two sets are less broadened
andmore deﬁned. This different behaviour betweenmetalla-cycles
Fig. 6 1H NMR spectra in CD3CN (21 ◦C) of metalla-cycles 3a and
3b, showing the pyridyl and ethylene region of the N«N linkers and the
aromatic region of the p-cym ligands.
incorporating bpe and bpa could be explained by a difference of
rigidity between bpe and bpa leading to different conformations
of the metalla-cycles 1a:1b and 3a:3b. Moreover a broadening of
the singlet associated to the ethane and ethylene protons of the
bpa and bpe linkers suggests non-equivalent signals in metalla-
cycles 1 and 3. As previously reported,14a in metalla-cycle 6a the
asymmetry of the 9,10-anthraquinonato-1,4-diolato ligand after
coordination to twometal centres does not affect the signals of the
pyridyl protons nor the ethylene protons. However, in the case of
metalla-cycle 6b, an important broadening of the ethane signal of
the bpa linkers is observed. This tends to conﬁrm an effect of the
rigidity of theN«N linker on the geometrical conformation of the
metalla-cycles, and the presence of two isomers inmetalla-cycles 6.
The cationic bpe-incorporating metalla-cycles 1a–7a have been
studied by electrospray ionisation mass spectrometry (ESI-MS).
In particular, a peak corresponding to [1a + (CF3SO3)2]2+ is
observed in the ESI mass spectrum at m/z 916.1. This peak is
unambiguously assigned on the basis of its characteristic Ru4
isotope pattern. Concerning the new bpa-incorporating metalla-
cycles 1b–7b, an interesting fragmentation was observed. Peaks
corresponding to [CLx + bpa + CF3SO3 + 1] are observed in
all mass spectra at m/z 919.1, 893.1, 960.1, 942.1, 993.1, 1043.1,
1093.1, respectively (Fig. 7).
The size of the metalla-cycles has been estimated using the
HyperChem software.26 As expected the simulations show an
almost identical sizes for metalla-cycles 1–3 and 5–7, while the
size of metalla-cycle 4 is somewhere in between. The presence of
bpe or bpa does not signiﬁcantly modify the size, the bpa linkers,
Fig. 5 Schematic representation of the two isomers of 1.
4
Fig. 7 ESI-MS of the peak envelopes corresponding to the fragmentation of [1b–7b][CF3SO3]4.
however, offer more ﬂexibility. Therefore, in this series, the size of
the metalla-cycles is related to the OO«OO and NO«NO linkers.
Models of the metalla-cycles are presented in Fig. 8, together with
an estimation of the corresponding cavity sizes.
The difference of cavity sizes for the three groups of metalla-
cycles (1–3; 4; 5–7), estimated by computational method, can be
linked with previous results and in particular with the accommo-
dation of small polycyclic aromatic hydrocarbon molecules into
the hydrophobic cavity of metalla-cycles 5a–7a.14a,c The hosting
ability of these three metalla-cycles towards planar aromatic guest
molecules such as pyrene, perylene and coronene was established
using different spectroscopic methods.14a,c Strong association
constants were estimated in solution for the corresponding host–
guest systems, indicating a great potential as host systems for this
kind of metalla-cycles. Similarly, Navarro and Barea have shown
that the tetranuclear metalla-cycles [(h6-p-cym)4Ru4(oxo)2(4,4¢-
bipyridine)2]4+ and [(h6-p-cym)4Ru4(oxo)2(4,7-phenanthroline)2]4+
interact weakly with guanosine monophosphate (GMP) and
adenosine monophosphate (AMP) in aqueous solution.9 There-
fore, we investigate the ability of metalla-cycles 1–7 to interact
with guanine and guanosine in solution (50 : 50 DMSO-d6 : D2O).
However, the 1H NMR spectra of the metalla-cycles were not
affected by gradual addition of these nucleotides, suggesting no in-
or out-of-cavity interactions under these experimental conditions.
Antiproliferative activity
The antiproliferative activities of the water-soluble metalla-cycles
containing the ligands 1,2-bis(4-pyridyl)ethylene (1a–7a) and
1,2-bis(4-pyridyl)ethane (1b–7b) were evaluated against the
Fig. 8 Estimated sizes (Ru–Ru separations) of the metalla-cycles 1–7.
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Table 1 IC50 values and resistance factors (RFs) of complexes 1a–7b in
A2780 and A2780cisR cell lines and metalla-cycles 8–129,10
Complex A2780 (IC50, mM) A2780cisR (IC50, mM) RF
1a 26.4 ± 1.0 112.7 ± 17.2 4.3
2a 4.2 ± 0.9 10.3 ± 2.6 2.5
3a 10.3 ± 1.2 23.3 ± 0.2 2.3
4a 10.3 ± 5.4 13.3 ± 6.1 1.3
5a 2.7 ± 1.0 2.5 ± 0.9 0.9
6a 9.4 ± 0.8 13.8 ± 3.6 1.5
7a 9.9 ± 1.8 8.5 ± 0.6 0.9
1b 35.5 ± 7.3 20.8 ± 5.3 0.6
2b 65.8 ± 9.6 75.3 ± 9.8 1.1
3b 144.7 ± 12.8 116.3 ± 9.2 0.8
4b 2.4 ± 1.1 5.9 ± 0.7 2.1
5b 2.6 ± 0.5 2.0 ± 0.3 0.7
6b 8.3 ± 0.2 7.6 ± 2.1 0.9
7b 17.5 ± 5.8 5.2 ± 1.4 0.3
8 19.0 4.6 0.2
9 15.0 8.3 0.6
10 0.8 ± 0.1 2.4 ± 0.1 3.0
11 0.2 ± 0.1 0.2 ± 0.1 1.0
12 3.3 ± 0.1 3.1 ± 0.1 0.9
Cisplatin 3.1 15.5 4.7
A2780 and A2780cisR ovarian cancer cell lines, and the results
are presented in Table 1. IC50 values on A2780 and A2780cisR
cancer cells of metalla-cycles [(h6-p-cym)4Ru4(oxo)2(4,4¢-
bipyridine)2]4+ (8), [(h6-p-cym)4Ru4(oxo)2(4,7-phenanthroline)2]4+
(9), [(h6-p-cym)4Ru4(dobq)2(4,7-phenanthroline)2]4+ (10), [(h6-p-
cym)4Ru4(donq)2(4,7-phenanthroline)2]4+ (11), and [(h6-p-cym)4-
Ru4(dcbq)2(4,7-phenanthroline)2]4+ (12), previously published by
Navarro and Barea are also given for comparison but were not
re-evaluated in this study.9,10 The molecular structures of these
metalla-cycles (8–12) are presented in Fig. 9.
Fig. 9 Molecular structures of metalla-cycles 8–12.9,10
All new metalla-cycles exhibit moderate to excellent activity
with IC50 values in the range 2–35 mM, except for metalla-
cycles 2b and 3b for which the antiproliferative activity is lower
by at least a factor 2 (see Table 1). Moreover, the activities
of the metalla-cycles are comparable to those of the metalla-
assemblies 8, 9 and 12, but remain slightly less active than the
phenanthroline derivatives 10 and 11.10 Phenanthroline is well
known for its interaction with DNA, and it might explain the
higher activity of the 4,7-phenanthroline metalla-cycles 10 and
11.27,28 Interestingly, metalla-cycle 1a is 4 times more active on the
non-resistant cisplatin cell line (A2780), while most complexes
show an almost identical or even a better cytotoxicity on the
cisplatin resistant cancer cell line (A2780cisR), as noted in Table
1. Overall, the average resistance factor (RF) value (RF =
IC50(A2780cisR)/IC50(A2780)) is more or less 1, thus conﬁrming
that metalla-cycles display a different mode of action than that of
cisplatin. A tendency often observed with arene ruthenium and
arene osmium metal-based drugs.29
In recent years, a large number of cationic polynuclear ruthe-
nium complexes have been evaluated as putative anticancer
agents.30 The high charge of these complexes not only facilitates
uptake to cancer cells,29a,31 it generates good DNA binding
systems.30 DNA remains the primary target for arene ruthenium
drugs,32 and as previously shown arene ruthenium metalla-cycles
are excellent DNA binding systems.16b,28 Therefore, the good
cytotoxicity observed here formetalla-cycles 1–7 is possibly related
with the DNA binding afﬁnities of these systems. Indeed, it
appears that metalla-cycles with multiple p-aromatic groups (4–
7) and those offering more ﬂexibility (4b–7b) are more active
against the ovarian cancer cell lines than the smaller assemblies (1–
3). However, despite this potential interaction with DNA, other
biological targets cannot be excluded and other mechanisms of
action can also play an important role in the biological activity of
these metalla-cycles.
Conclusion
A series of cationic metalla-cycles based on arene ruthenium units
have been prepared and characterised by different spectroscopic
methods. These water-soluble compounds were screened for in
vitro anticancer activity against the A2780 andA2780cisR ovarian
cancer cell lines and allmetalla-cycles exhibitmoderate to excellent
activity. Moreover some metalla-cycles were found to be more
active on the cisplatin resistant cancer cell line than on the cisplatin
sensitive line, suggesting a different biological mechanism than
that of cisplatin.
Experimental
General details
The [Ru(h6-p-cym)Cl2]2,33 the dinuclear arene ruthenium
complexes [Ru2(h6-p-cym)2(OO«OO)Cl2] (OO«OO = ox,6b
dobq,15a donq,15b doaq,34 dotq14a), [Ru2(h6-p-cym)2(NO«NO)Cl2]
(NO«NO = oxo9) and the metalla-cycles 2a,14b 4a,17 5a,14b 6a,14c
and 7a14c were prepared according to publishedmethods. All other
reagents were commercially available (Sigma-Aldrich) and used as
received. The 1H and 13C{1H} NMR spectra were recorded on
a Bruker AMX 400 spectrometer using the residual protonated
solvent as internal standard. Infrared spectra were recorded
as KBr pellets on a Perkin-Elmer FTIR 1720 X spectrometer.
UV-visible absorption spectra were recorded on an Uvikon 930
spectrophotometer using precision cells made of quartz (1 cm).
Electrospray ionisation mass spectra were obtained in positive-
ion mode on a Bruker FTMS 4.7T BioAPEX II mass spectrom-
eter. Microanalysis was performed by the Mikroelementarisches
Laboratorium, ETH Zu¨rich (Switzerland).
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Synthesis of metalla-clip CL1Cl2
n-BuLi (0.30 mL, 0.48 mmol) was added to a solution of N,N¢-
dimethyloxamide (oxa-H2) (27.9 mg, 0.24 mmol) in THF (15 mL)
at -78 ◦C. The reaction mixture was stirred and warmed to room
temperature (2 h). Then the mixture was added to a solution of
[Ru(h6-p-cym)Cl2]2 (146.9 mg, 0.24 mmol) in THF (5 mL), and
stirred overnight. The solvent was evaporated in vacuo and the
residue washed several times with water, and ﬁnally with diethyl
ether and pentane before being dried.
CL1Cl2: Yield: 96 mg (61%). IR: n (cm-1): 3060 (w, CHaryl), 1609
(s, C O). 1HNMR (400MHz, CD2Cl2, 298K): d (ppm) = 5.35 (d,
3J = 5.7 Hz, 2 H, Har), 5.32 (d, 3J = 5.8 Hz, 2 H, Har), 5.26 (d, 2 H,
Har), 5.06 (d, 2 H, Har), 3.27 (s, 6 H, CH3), 2.71 (sept, 3J = 2.7 Hz,
2 H, CH(CH3)2), 2.12 (s, 6 H, CH3), 1.21 (d, 6 H, CH(CH3)2),
1.19 (d, 6 H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2, 298
K): d (ppm) = 170.3 (CO), 100.8 (Car), 95.8 (Car), 81.9 (CHar), 81.3
(CHar), 80.9 (CHar), 79.6 (CHar), 38.0 (CH3), 31.5 (CH(CH3)2),
22.6 (CH(CH3)2), 22.5 (CH(CH3)2), 18.7 (CH3). UV-vis (1.0 ¥ 10-5
M, CH2Cl2): lmax 306 nm (e = 2.96 ¥ 105 M-1 cm-1). Elemental
Analysis (%): Calc. for C24H34Cl2N2O2Ru2 (655.6): C, 43.97; H,
5.23; N, 4.27; Found: C, 43.86; H, 5.22; N, 4.27%.
Synthesis of metalla-cycles [1a][CF3SO3]4, [3a][CF3SO3]4 and
[1b–7b][CF3SO3]4
AgCF3SO3 (149.0 mg, 0.58 mmol) was added to a suspension of
[Ru2(h6-p-cym)2(OO«OO)Cl2] or [Ru2(h6-p-cym)2(NO«NO)Cl2]
(oxa (1a, 1b; 190.1 mg), ox (2b; 182.6 mg), oxo (3a, 3b; 202.6
mg), dobq (4b; 196.9 mg), donq (5b; 211.4 mg), doaq (6b; 225.9
mg), dotq (7b; 240.4 mg); 0.29 mmol) in methanol (100 mL) at
60 ◦C and stirred for 12 h, followed by ﬁltration to remove AgCl.
Then, 1,2-bis(4-pyridyl)ethylene (1a, 3a; 52.8 mg, 0.29 mmol) or
1,2-bis(4-pyridyl)ethane (1b–7b; 53.4mg, 0.29mmol)was added to
the ﬁltrate. The solution was stirred at 60 ◦C for 24 h. The solvent
was removed and the residue extracted with dichloromethane. The
ﬁltrate was concentrated to about 2 mL and diethyl ether added.
The precipitate was washed with diethyl ether (3 ¥ 50 mL) and
pentane (3 ¥ 50 mL) and dried in vacuo to give the corresponding
product as powder.
[1a][CF3SO3]4: Yield: 200 mg (65%). IR: n (cm-1): 3070 (m,
CHar), 1616 (s, C O), 1256 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 7.96 (br, 4 H, Ha), 7.94 (br, 4 H, Ha), 7.53 (br,
4 H, Hb), 7.51 (br, 4 H, Hb), 7.44 (br, 4 H, HC C), 5.87 (m, 4 H,
Har), 5.77 (m, 4 H, Har), 5.38 (m, 4 H, Har), 5.30 (m, 4 H, Har),
3.51 (s, 12 H, CH3), 2.75 (m, 4 H, CH(CH3)2), 1.96 (s, 12 H, CH3),
1.30 (m, 24 H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3CN,
298 K): d (ppm) = 170.6 (CO), 152.8 (CHa), 145.8 (Cpyr), 132.0
(HC CH), 123.4 (CHb), 102.4 (Car), 99.7 (Car), 86.5 (CHar), 84.5
(CHar), 81.7 (CHar), 78.4 (CHar), 37.9 (CH3), 31.0 (CH(CH3)2),
21.6 (CH(CH3)2), 16.9 (CH3). UV-vis (1.0 ¥ 10-5 M, CH2Cl2):
lmax 269 nm (e = 3.15 ¥ 105 M-1 cm-1), lmax 340 nm (e = 0.61 ¥ 105
M-1 cm-1). Elemental Analysis (%): Calc. for C76H88F12N8O16Ru4S4
(2130.1): C, 42.85; H, 4.16; N, 5.26; Found: C, 42.76; H, 4.30; N,
5.18%.
[3a][CF3SO3]4: Yield: 208 mg (65%). IR: n (cm-1): 3077 (m,
CHar), 1712 (s, C N), 1612 (s, C O), 1259 (s, CF). 1H NMR
(400 MHz, CD3CN, 298 K): d (ppm) = 9.98 (s, 2 H, NH), 7.97 (br,
4 H, Ha), 7.94 (br, 4 H, Ha), 7.56 (br, 4 H, Hb), 7.53 (br, 4 H, Hb),
7.40 (br, 4 H, HC C), 6.06 (m, 4 H, Har), 6.03 (m, 4 H, Har), 5.94 (m,
4 H, Har), 5.50 (m, 4 H, Har), 2.75 (m, 4 H, CH(CH3)2), 1.96 (s, 12
H, CH3), 1.24 (m, 12 H, CH(CH3)2), 1.15 (m, 12 H, CH(CH3)2).
13C{1H}NMR (100MHz, CD3CN, 298K): d (ppm) = 178.9 (CO),
162.4 (CN), 154.6 (CHa), 146.1 (Cpyr), 132.1 (HC CH), 124.0
(CHb), 106.0 (Car), 99.4 (Car), 83.9 (CHar), 83.7 (CHar), 83.6 (CHar),
80.7 (CHar), 30.9 (CH(CH3)2), 21.5 (CH(CH3)2), 17.0 (CH3). UV-
vis (1.0 ¥ 10-5 M, CH2Cl2): lmax 265 nm (e = 3.00 ¥ 105 M-1 cm-1),
lmax 331 nm (e = 0.51 ¥ 105 M-1 cm-1). Elemental Analysis (%):
Calc. for C76H78F12N10O20Ru4S4 (2212.0): C, 41.27; H, 3.55; N,
6.33; Found: C, 41.20; H, 3.66; N, 6.22%.
[1b][CF3SO3]4: Yield: 191 mg (62%). IR: n (cm-1): 3073 (m,
CHar), 1620 (s, C O), 1259 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 7.89 (d, 4 H, 3J = 5.1 Hz, Ha), 7.67 (d, 4 H,
Ha), 7.09 (d, 4 H, 3J = 5.4 Hz, Hb), 6.84 (d, 4 H, Hb), 5.81 (d,
4 H, 3J = 5.8 Hz, Har), 5.73 (d, 4 H, 3J = 6.2 Hz, Har), 5.45
(d, 4 H, Har), 5.31 (d, 4 H, Har), 3.46 (s, 12 H, CH3), 3.36 (s, 8
H, Hbpa), 2.70 (sept, 4 H, 3J = 8.2 Hz, CH(CH3)2), 1.81 (s, 12
H, CH3), 1.78 (d, 12 H, CH(CH3)2), 1.22 (d, 12 H, CH(CH3)2).
13C{1H}NMR (100MHz, CD3CN, 298K): d (ppm) = 170.1 (CO),
153.8 (CHa), 153.5 (CHa), 152.8 (Cpyr), 150.6 (Cpyr), 129.1 (CHb),
128.0 (CHb), 103.5 (Car), 99.8 (Car), 86.7 (CHar), 84.7 (CHar), 82.6
(CHar), 79.3 (CHar), 38.5 (CH3), 36.0 (CHbpa), 22.5 (CH(CH3)2),
22.4 (CH(CH3)2), 18.1 (CH3). UV-vis (1.0 ¥ 10-5 M, CH2Cl2):
lmax 727 nm (e = 3.08 ¥ 105 M-1 cm-1), lmax 342 nm (e = 0.65 ¥ 105
M-1 cm-1). Elemental Analysis (%): Calc. for C76H92F12N8O16Ru4S4
(2134.1): C, 42.77; H, 4.35; N, 5.25; Found: C, 42.68; H, 4.48; N,
5.16%.
[2b][CF3SO3]4: Yield: 205 mg (68%). IR: n (cm-1): 3070 (m,
CHar), 1613 (s, C O), 1259 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 7.74 (d, 8 H, 3J = 6.3 Hz, Ha), 7.00 (d, 8 H,
Hb), 5.82 (d, 8 H, 3J = 6.1 Hz, Har), 5.69 (d, 8 H, Har), 3.25 (s,
8 H, Hbpa), 2.80 (sept, 4 H, 3J = 2.5 Hz, CH(CH3)2), 2.15 (s, 12
H, CH3), 1.30 (d, 24 H, CH(CH3)2). 13C{1H} NMR (100 MHz,
CD3CN, 298 K): d (ppm) = 173.0 (CO), 151.8 (CHa), 145.2 (Cpyr),
127.3 (CHb), 100.2 (Car), 98.7 (Car), 84.9 (CHar), 83.7 (CHar), 33.0
(CHbpa), 32.2 (CH(CH3)2), 22.7 (CH(CH3)2), 19.2 (CH3). UV-vis
(1.0 ¥ 10-5 M, CH2Cl2): lmax 267 nm (e = 2.89 ¥ 105 M-1 cm-1), lmax
340 nm (e = 0.45 ¥ 105 M-1 cm-1). Elemental Analysis (%): Calc.
for C72H80F12N4O20Ru4S4 (2081.9): C, 41.54; H, 3.87; F, 10.95; N,
2.69; Found: C, 41.45; H, 4.03; N, 2.65%.
[3b][CF3SO3]4: Yield: 251 mg (78%). IR: n (cm-1): 3077 (m,
CHar), 1709 (s, C N), 1594 (s, C O), 1260 (s, CF). 1H NMR
(400 MHz, CD3CN, 298 K): d (ppm) = 9.98 (s, 2 H, NH), 8.02
(m, 4 H, Ha), 7.42 (m, 4 H, Ha), 7.06 (m, 4 H, Hb), 6.92 (m, 4 H,
Hb), 6.02 (m, 8 H, Har), 5.90 (m, 4 H, Har), 5.80 (m, 4 H, Har), 3.24
(br, 8 H, Hbpa), 2.73 (m, 4 H, CH(CH3)2), 2.09 (s, 12 H, CH3), 1.23
(m, 12 H, CH(CH3)2), 1.15 (m, 12 H, CH(CH3)2). 13C{1H} NMR
(100 MHz, CD3CN, 298 K): d (ppm) = 178.9 (CO), 162.4 (CN),
154.6 (CHa), 146.2 (Cpyr), 124.1 (CHb), 106.1 (Car), 99.3 (Car), 84.0
(CHar), 83.8 (CHar), 83.7 (CHar), 83.6 (CHar), 30.9 (CH(CH3)2),
21.5 (CH(CH3)2), 17.1 (CH3). UV-vis (1.0 ¥ 10-5 M, CH2Cl2): lmax
269 nm (e = 2.81 ¥ 105 M-1 cm-1), lmax 374 nm (e = 0.20 ¥ 105 M-1
cm-1). Elemental Analysis (%): Calc. for C76H82F12N10O20Ru4S4
(2216.0): C, 41.19; H, 3.73; N, 6.32; Found: C, 41.15; H, 3.87; N,
6.23%.
[4b][CF3SO3]4: Yield: 259 mg (82%). IR: n (cm-1): 3068 (m,
CHar), 1598 (s, C O), 1260 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 7.78 (d, 3J = 6.1 Hz, 8 H, Ha), 7.13 (d, 8 H,
7
Hb), 5.92 (d, 3J = 6.3 Hz, 8 H, Har), 5.86 (d, 8 H, Har), 5.48 (s, 4 H,
Hdobq), 3.26 (s, 8 H, Hbpa), 2.85 (sept, 3J = 2.5 Hz, 4 H, CH(CH3)2),
2.10 (s, 12 H, CH3), 1.30 (d, 24 H, CH(CH3)2). 13C{1H} NMR
(100 MHz, CD3CN, 298 K): d (ppm) = 171.4 (CO), 153.2 (CHa),
150.7 (Cpyr), 130.1 (CHb), 114.6 (CHdobq), 108.2 (Cdobq), 102.1 (Car),
99.8 (Car), 84.2 (CHar), 84.0 (CHar), 29.3 (CHbpa), 30.0 (CH(CH3)2),
20.9(CH(CH3)2), 17.4 (CH3). UV-vis (1.0 ¥ 10-5 M, CH2Cl2): lmax
265 nm (e = 3.01 ¥ 105 M-1 cm-1), lmax 317 nm (e = 0.46 ¥ 105 M-1
cm-1), lmax 510 nm (e = 0.43 ¥ 105 M-1 cm-1). Elemental Analysis
(%): Calc. for C80H84F12N4O20Ru4S4 (2182.1): C, 44.03; H, 3.88; N,
2.57; Found: C, 43.92; H, 4.00; N, 2.50%.
[5b][CF3SO3]4: Yield: 248 mg (75%). IR: n (cm-1): 3070 (m,
CHar), 1619 (s, C O), 1259 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 7.94 (d, 3J = 6.3 Hz, 8 H, Ha), 7.03 (d, 8 H, Hb),
6.96 (s, 8 H, Hdonq), 5.66 (d, 3J = 6.3 Hz, 8 H, Har), 5.44 (d, 8 H,
Har), 3.21 (s, 8 H, Hbpa), 2.82 (sept, 3J = 2.1 Hz, 4 H, CH(CH3)2),
2.10 (s, 12 H, CH3), 1.30 (d, 24 H, CH(CH3)2). 13C{1H} NMR
(100 MHz, CD3CN, 298 K): d (ppm) = 170.3 (CO), 152.9 (CHa),
151.9 (Cpyr), 137.2 (CHb), 125.8 (CHdonq), 111.3 (Cdonq), 103.4 (Car),
99.0 (Car), 83.7 (CHar), 82.8 (CHar), 31.1 (CHbpa), 30.6 (CH(CH3)2),
21.4 (CH(CH3)2), 16.5 (CH3). UV-vis (1.0 ¥ 10-5 M, CH2Cl2):
lmax 266 nm (e = 2.99 ¥ 105 M-1 cm-1), lmax 327 nm (e = 0.30 ¥
105 M-1 cm-1), lmax 454 nm (e = 0.22 ¥ 105 M-1 cm-1), lmax 720
nm (e = 0.08 ¥ 105 M-1 cm-1). Elemental Analysis (%): Calc. for
C88H88F12N4O20Ru4S4 (2282.2): C, 46.31; H, 3.89; F, 9.99; N, 2.45;
Found: C, 46.16; H, 3.99; N, 2.39%.
[6b][CF3SO3]4: Yield: 266 mg (77%). IR: n (cm-1): 3070 (m,
CHar), 1618 (s, C O), 1260 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 8.46 (d, 3J = 6.1 Hz, 8 H, Ha), 8.01 (d, 8 H,
Hb), 7.90 (m, 4 H, Hdoaq), 7.06 (s, 4 H, Hdoaq), 5.78 (d, 3J = 6.3 Hz,
4 H, Har), 5.73 (d, 3J = 6.1 Hz, 4 H, Har), 5.54 (d, 4 H, Har), 5.50
(d, 4 H, Har), 3.21 (br, 8 H, Hbpa), 2.92 (sept, 3J = 2.3 Hz, 4 H,
CH(CH3)2), 2.11 (s, 12 H, CH3), 1.34 (d, 12 H, CH(CH3)2), 1.30
(d, 12 H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3CN, 298
K): d (ppm) = 171.5 (CO), 170.7 (CO), 155.4 (CHa), 151.9 (Cpyr),
139.9 (CHdoaq), 138.3 (CHb), 136.6 (CHdoaq), 134.3 (Cdoaq), 132.0
(Cdoaq), 128.2 (CHdoaq), 104.7 (Car), 100.3 (Car), 85.4 (CHar), 84.8
(CHar), 83.9 (CHar), 82.0 (CHar), 29.2 (CHbpa), 31.2 (CH(CH3)2),
21.2 (CH(CH3)2), 21.0 (CH(CH3)2), 17.0 (CH3). UV-vis (1.0 ¥ 10-5
M, CH2Cl2): lmax 264 nm (e = 3.01 ¥ 105 M-1 cm-1), lmax 324 nm (e =
0.32 ¥ 105 M-1 cm-1), lmax 417 nm (e = 0.25 ¥ 105 M-1 cm-1), lmax
683 nm (e = 0.13 ¥ 105 M-1 cm-1). Elemental Analysis (%): Calc. for
C96H92F12N4O20Ru4S4 (2382.3): C, 48.40; H, 3.89; N, 2.35; Found:
C, 48.22; H, 4.001; N, 2.30%.
[7b][CF3SO3]4: Yield: 255 mg (71%). IR: n (cm-1): 3068 (m,
CHar), 1612 (s, C O), 1260 (s, CF). 1HNMR (400MHz, CD3CN,
298 K): d (ppm) = 8.53 (d, 3J = 6.8 Hz, 8 H, Ha), 7.97 (d, 3J =
8.4 Hz, 8 H, Hdotq), 7.89 (d, 8 H, Hb), 6.88 (d, 8 H, Hdotq), 5.85
(d, 3J = 6.1 Hz, 8 H, Har), 5.61 (d, 8 H, Har), 3.33 (s, 8 H, Hbpa),
3.00 (sept, 3J = 2.5 Hz, 4 H, CH(CH3)2), 2.12 (s, 12 H, CH3),
1.37 (d, 24 H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3CN,
298 K): d (ppm) = 170.4 (CO), 153.1 (CHa), 152.5 (Cpyr), 139.1
(CHb), 134.7 (CHdotq), 133.6 (Cdotq), 133.5 (Cdotq), 132.4 (CHdotq),
100.2 (Car), 96.0 (Car), 84.7 (CHar), 83.9 (CHar), 32.3 (CHbpa), 31.3
(CH(CH3)2), 19.8 (CH(CH3)2), 17.0 (CH3). UV-vis (1.0 ¥ 10-5 M,
CH2Cl2): lmax 267 nm (e = 3.07 ¥ 105 M-1 cm-1), lmax 327 nm (e =
0.44 ¥ 105 M-1 cm-1), lmax 379 nm (e = 0.38 ¥ 105 M-1 cm-1), lmax
409 nm (e = 0.29 ¥ 105 M-1 cm-1), lmax 588 nm (e = 0.16 ¥ 105 M-1
cm-1), lmax 636 nm (e = 0.19 ¥ 105 M-1 cm-1). Elemental Analysis
(%): Calc. for C104H96F12N4O20Ru4S4 (2482.4): C, 50.32; H, 3.90;
N, 2.26; Found: C, 50.11; H, 3.97; N, 2.20%.
Cell culture and inhibition of cell growth
Human A2780 and A2780cisR ovarian carcinoma cells were
obtained from the European Centre of Cell Cultures (ECACC,
Salisbury, UK) and maintained in culture as described by the
provider. The cells were routinely grown in RPMI 1640 medium
with GlutaMAXTM containing 10% foetal calf serum (FCS) and
antibiotics (penicillin and streptomycin) at 37 ◦C and 5% CO2.
For the evaluation of growth inhibition tests, the cells were seeded
in 96-well plates (25 ¥ 103 cells per well) and grown for 24 h in
complete medium. Solutions of the compounds were applied by
diluting a freshly prepared stock solution of the corresponding
compound in RPMI medium. The stock solutions of metal com-
plexes were prepared by dissolving the compounds in 0.5 mL of
DMSO to reach a concentration of 10-2 M. They were then diluted
in RPMImedium and added to the wells (100 mL) to obtain a ﬁnal
concentration ranging between 0 and 150 mM for 72 h incubation.
DMSO at comparable concentrations did not show any effects on
cell cytotoxicity. Following drug exposure, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the
cells at a ﬁnal concentration of 0.25 mg mL-1 and incubated
for 2 h, then the culture medium was aspirated and the violet
formazan (artiﬁcial chromogenic precipitate of the reduction of
tetrazolium salts by dehydrogenases and reductases) dissolved
in DMSO. The optical density of each well (96-well plates)
was quantiﬁed three times in tetraplicates at 540 nm using a
multiwell plate reader (iEMS Reader MF, Labsystems, US), and
the percentage of surviving cells was calculated from the ratio
of absorbance of treated to untreated cells. The half maximal
inhibitory concentration (IC50) values for the inhibition of cell
growth were determined by ﬁtting the plot of the logarithmic
percentage of surviving cells against the logarithm of the drug
concentration using a linear regression function and the values
obtained are reported in Table 1.
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